Energesis is testing the waters for a Regulation Crowdfunding offering on BioTech Funding Portal. Learn more →
Obesity therapeutics · Boston, MA
Bringing new energy to the fight against obesity.
Energesis Pharmaceuticals is developing a new class of obesity drug candidates designed to safely increase the body’s energy expenditure by restoring a healthy level of brown fat.
Lead program: EGS-2632
A proprietary oral combination candidate being developed to increase brown fat-mediated energy expenditure and support high-quality weight loss solely from fat.
5 key takeaways
A differentiated approach to obesity treatment
Energesis is focused on brown fat recruitment, energy expenditure, and the potential for completely muscle-preserving weight loss without relying only on appetite suppression.
1
Targeting Energy Expenditure
Most obesity drugs reduce energy intake; Energesis is developing drug candidates intended to increase energy expenditure.
2
Built Around Brown Fat
Brown fat is an energy-burning tissue that helps regulate body weight, but people with obesity generally have lower brown fat levels than lean individuals.
3
Human Discovery Platform
Energesis uses adult human brown adipocyte stem/progenitor cells to discover compounds and targets that promote new brown fat formation.
4
Lead Oral Candidate
EGS-2632 is a proprietary oral combination of two previously approved drugs being developed for obesity.
5
Potential GLP-1 Complement
In preclinical studies, EGS-2632 showed synergistic efficacy when combined with marketed GLP-1 agents.
The science
Weight has two sides. We work on the one that no marketed drug addresses.
Most obesity drugs help people eat less and take in fewer calories. In contrast, Energesis is developing oral drug candidates designed to help the body burn more calories, by restoring a healthy level of brown fat.
Energy in
Appetite-based drugs
GLP-1 medicines reduce food intake and have changed obesity care. Many patients still face tolerability issues, loss of lean mass and weight regain after stopping these drugs.
Energy out
Brown fat
Brown fat burns energy from sugars and fats and releases it as heat. Adults carry only about 50 to 400 grams, and people with obesity generally have less than lean individuals. Our candidates are designed to create more of it.
Make more brown fat. Let the body do the rest. Earlier drugs tried to stimulate the little brown fat people with obesity have, and this was insufficient. They also stimulated the heart in a potentially unsafe way. We take a different route.
Patient need
Why better obesity treatments matter
Obesity is a chronic disease that affects health, mobility, confidence, and quality of life. Although current therapies have advanced the field, many patients still face important challenges, including tolerability issues, weight regain after discontinuation, and loss of lean mass during treatment.
Energesis is pursuing a different biological strategy focused on increasing energy expenditure rather than reducing food intake.
>40%
U.S. adults living with obesity
~900M
Adults globally living with obesity
GLP-1s
Significant unmet needs remain
Body weight reflects a balance between energy intake and energy expenditure. Illustrative conceptual graphic.
Better obesity treatment is about more than weight loss. It is about daily life, long-term health, and sustainable wellbeing.
Lead candidate
EGS-2632
A proprietary oral combination of two previously approved drugs, used together at a fraction of their approved doses and being developed for obesity.
Significant weight loss
Statistically and clinically significant in diet-induced obese mice
Weight loss is from fat
Lean mass completely preserved
No drop in food intake
Energy expenditure rose through increased brown fat mass
Synergy with GLP-1s
More than additive weight loss alongside marketed GLP-1 drugs
I think that Energesis is developing a treatment for obesity that would approach the problem in a new way. By increasing metabolic rate, it could certainly cause weight loss without muscle wasting. It could also complement any of the drugs approved by the FDA for obesity. All the presently FDA-approved products are predicated on reducing appetite to treat the disease. All drugs that reduce appetite decrease metabolic rate, which sets the stage for weight regain if the medications are dose-reduced or discontinued. While still early, it's potentially an elegant solution.
Our campaign
Help bring new energy to the fight against obesity.
Energesis is testing the waters for a potential Regulation Crowdfunding offering on BioTech Funding Portal. Watch our video, read about our science and ask our founders questions.
Until a formal campaign is launched no money or other consideration is being solicited, and if sent in response, will not be accepted. No offer to buy securities can be accepted and no part of the purchase price can be received until an offering statement is filed and only through BioTech Funding Portal. Any indication of interest involves no obligation or commitment of any kind.